Accord Drug Patent Portfolio

Accord owns 1 orange book drug protected by 4 US patents Given below is the list of Accord's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11717555 Pharmaceutical compositions having a selected release duration 01 Jan, 2039
Active
US10646572 Pharmaceutical compositions with enhanced stability 16 Jan, 2027
Active
US9572857 Pharmaceutical compositions with enhanced stability 16 Jan, 2027
Active
US9744207 Pharmaceutical compositions with enhanced stability 16 Jan, 2027
Active


Given below is the list of recent legal activities going on the following drug patents of Accord.

Activity Date Patent Number
Patent litigations
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US9572857
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US10646572
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US9744207
transaction for FDA Determination of Regulatory Review Period 07 Feb, 2024 US9744207
transaction for FDA Determination of Regulatory Review Period 07 Feb, 2024 US9572857
transaction for FDA Determination of Regulatory Review Period 07 Feb, 2024 US10646572
Payment of Maintenance Fee, 4th Year, Large Entity 20 Oct, 2023 US10646572
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 19 Oct, 2023 US10646572
Email Notification 08 Aug, 2023 US11717555
Patent eGrant Notification 08 Aug, 2023 US11717555
Recordation of Patent Grant Mailed 08 Aug, 2023 US11717555
Mail Patent eGrant Notification 08 Aug, 2023 US11717555
Electronic Review 08 Aug, 2023 US11717555
Patent Issue Date Used in PTA Calculation 08 Aug, 2023 US11717555
Recordation of Patent eGrant 08 Aug, 2023 US11717555


Accord's Family Patents

Accord drugs have patent protection in a total of 15 countries. It's US patent count contributes only to 31.8% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Accord Drug List

Given below is the complete list of Accord's drugs and the patents protecting them.


1. Camcevi Kit

Camcevi Kit is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11717555 Pharmaceutical compositions having a selected release duration 01 Jan, 2039
(14 years from now)
Active
US10646572 Pharmaceutical compositions with enhanced stability 16 Jan, 2027
(2 years from now)
Active
US9572857 Pharmaceutical compositions with enhanced stability 16 Jan, 2027
(2 years from now)
Active
US9744207 Pharmaceutical compositions with enhanced stability 16 Jan, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Camcevi Kit's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Accord News

G-CSF and G-CSF Biosimilars Market Expected to Grow by 2032 Due to Rising Cancer Cases - openPR.com

25 Nov, 2024

Amgen Files Lawsuit Against Accord Over Proposed Biosimilar of Prolia® / Xgeva® under BPCIA

21 Nov, 2024

FDA gives the green light to Stelara biosimilar from Dong-A ST

15 Oct, 2024

See More